Psychedelic Spotlight News

Interview With Timothy Ko

Interview With Timothy Ko

Listen, Podcasts

CEO of Entheon Biomedical, Timothy Ko, discusses how the company plans to utilize the psychedelic compound, DMT, to treat a variety of addictions.

New Players, BUY Ratings, Financial Results & MORE ( MINDMED, NUMI, CMPS, MYCO, FTRP, HAVN, DMT)

New Players, BUY Ratings, Financial Results & MORE ( MINDMED, NUMI, CMPS, MYCO, FTRP, HAVN, DMT)

Listen, Videos

There were A LOT OF DEVELOPMENTS THIS WEEK, so strap on your seat belts and let’s dive into what happened this week with: MindMed ( MMED / MNMD / MMQ ), Compass Pathways (CMPS), NUMINUS (NUMI), Fieldtrip Health (FTRP / FTRPF), Mydecine ( MYCO / MYCOF), HAVN Labs
( HAVN / HAVLF), Novamind ( NM / NVMDF), Champignon Brands aka Braxia Scientific
(old ticker :SHRM / new ticker: BRAX / BRAXF), Nova Mentis (NOVA / NMLSF) and Small Pharma (DMT).

Timestamps:
0:00 – Intro
0:54 – MindMed’s (MMED / MNMD) Project Angie Announcement
1:47 – Compass Pathways (CMPS) Q1 Financial Results Date & Business Updates
3:16 – Analyst Coverage and Buy Ratings for CMPS
4:35 – Mydecine ( MYCO / MYCOF) 2020 Financial Results & Business Highlights
9:17 – Numinus Wellness (NUMI) Q2 Financial Results
11:25 – Field Trip Health (FTRP/ FTRPF) Opens more clinics
12:19 – Novamind ( NM / NVMDF) doubling its clinics
14:25 – Champignon Brands (SHRM /SHRMF) changing its named to Braxia Scientific (BRAX / BRAXF)
15:31 – NEW DMT company that began trading on may 6th under the name SMALL PHARMA ( DMT)
17:19 – HAVN Labs (HAVN) opens a new lab in Jamaica
17:50 – Nova Mentis launches a new clinical study using psilocybin to treat autism

Link to MindMed’s Project Angie Press release:
https://mindmed.co/news/press-release/mindmed-announces-project-angie-targeting-the-treatment-of-pain-with-psychedelics/

Link to Compass Pathways Q1 financial Results date:
https://ir.compasspathways.com/news-releases/news-release-details/compass-pathways-plc-announce-first-quarter-2021-financial

Link to Compass Pathways (CMPS) analyst ratings: https://www.marketbeat.com/stocks/NASDAQ/CMPS/price-target/

Link to Mydecine ( MYCO/ MYCOF) Full Year 2020 Financial results Plus business updates
https://www.globenewswire.com/news-release/2021/05/03/2221266/0/en/Mydecine-Reports-Full-Year-2020-Financial-Results-and-Provides-Business-Update.html

Link to Numinus (NUMI) Q2 2021 Financial Results:
https://www.newswire.ca/news-releases/numinus-wellness-q2-2021-results-highlighted-by-17-25-million-financing-mindspace-wellbeing-acquisition-and-clinical-trial-collaboration-with-maps-pbc-846735411.html

Link to Field Trip’s (FTPR / FTPRF) 7th Psychedelic-assisted therapy Clinic:
https://psilocybinalpha.com/news/field-trip-health-ltd-announces-opening-of-psychedelic-enhanced-therapy-center-in-houston-locations-of-next-5-field-trip-health-centers

Link to Novamind’s (NM / NVMDF) Ketamine Clinic article:
https://novamind.ca/2021-05-04-novamind-doubles-in-size-adds-four-new-psychedelic-mental-health-clinics/

Link to Champignon Brands ( SHRM/ SHRMF) announcing their name change to Braxia Scientific (BRAX / BRAXF):
https://thedeepdive.ca/champignon-brands-to-change-name-to-braxia-scientific/

Link to Small Pharma ( DMT):
https://psilocybinalpha.com/news/small-pharma-completes-reverse-take-over-transaction

Link to Havn’s (HAVN / HAVLF) Jamaica lab:
https://www.psychedelicfinance.com/articles/havn-labs-jamaica-facility-now-fully-operational

Link to Nova Mentis launching a clinical study to learn more about Autism:
https://psilocybinalpha.com/news/nova-mentis-launches-autism-clinical-study

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
editing by: @themyaholy
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #Numi #CMPS

AI CREATING Psychedelics : Is this the FUTURE of the Psychedelic Industry? (+ MDMA Study Results)

AI CREATING Psychedelics : Is this the FUTURE of the Psychedelic Industry? (+ MDMA Study Results)

Learn, Videos

AI CREATING Psychedelics : Is this the FUTURE of the Psychedelic Industry? (+ MDMA Study Results) Today, we’ll be sharing some GAME changing news for the entire psychedelic-medicines industry!

First, we’ll start with some inspiring results from a few MDMA studies and their implications for companies such as Numinus (NUMI), MindMed (MMED / MNMD / MMQ) and Atai Life Sciences. First we’ll cover MAPS’ Phase III MDMA To Treat PTSD Trial Results. Then, we’ll focus on another study’s results, which implies that MDMA could be an effective treatment for alcoholism.

Then, we’ll shift our focus towards an update on Texas, one of the more conservative U.S. states, and its approval of a Psychedelics Research Bill.

Finally, we’ll share some of the oddest and most exciting news from this week: AI might potentially disrupt the psychedelic industry in the next few decades through the creation of psychedelic medicines.

Timestamps:

0:00 – Intro
1:24 – Maps Phase III Trial Testing MDMA to treat PTSD RESULTS & Implications for
Numinus (NUMI), MindMed (MMED / MNMD / MMQ ), Atai, etc.
3:23 – Imperial College of London Study testing MDMA-assisted psychotherapy to treat Alcoholism
7:29 – Texas House Approves a Psychedelic Research Bill
9:34 – Scientists are Using AI to Develop New Psychedelic Drugs

Links to Maps Phase III MDMA trial to treat PTSD : https://www.nytimes.com/2021/05/03/health/mdma-approval.html
https://maps.org/news/media/9122-maps-phase-3-trial-of-mdma-assisted-therapy-for-ptsd-achieves-successful-results-for-patients-with-severe-chronic-ptsd

Links to the Imperial College of London MDMA study to treat alcoholism: https://www.telegraph.co.uk/health-fitness/body/mdma-cured-alcoholism-inside-remarkable-ectsasy-trial-offering/
https://www.telegraph.co.uk/news/2021/02/22/mdma-could-used-treat-alcohol-addiction/

Link to the Texas House Psychedelics Research Bill: https://www.marijuanamoment.net/texas-house-approves-psychedelics-research-bill-as-marijuana-reform-measures-also-advance/

Link to the article “Scientists are Using AI to Develop New Psychedelic Drugs: https://doubleblindmag.com/artificial-intelligence/

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #PsychedelicStocks #MNMD

End of content

End of content